Anterra Capital raises $100M as generalist VCs abandon agtech
Anterra Capital closed $100M for its third fund targeting $200M, backed by Rabobank, Novo Holdings, and Zoetis, a counter-cyclical bet that AI adoption in agriculture will reward disciplined operators over hype.
FDA delays LEQEMBI weekly Alzheimer's drug by three months
FDA extended review of Eisai's weekly subcutaneous lecanemab formulation to August 24, 2026, signaling continued scrutiny of anti-amyloid Alzheimer's therapies despite recent approvals.
Neomorph Closes $100M Series B With First Patient Dosed
Neomorph raised $100M in Series B funding to advance NEO-811, a molecular glue degrader with a first-in-human patient already dosed in Phase 1/2 trials for renal cancer, backed by Deerfield Management and pharma giants Novo Nordisk, Biogen, and AbbVie.